Arixtra (fondaparinux) has been approved for the treatment of acute symptomatic spontaneous superficial-vein thrombosis of the lower limbs without concomitant deep-vein thrombosis (DVT).
Treatment should be initiated as soon as possible following diagnosis and after exclusion of concomitant DVT or superficial-vein thrombosis within 3cm of the sapheno-femoral junction.
Therapy with Arixtra should be continued for ?30—45 days. Patients may self inject if willing ?and able to do so, following clear instruction by their physician.
Further information: GlaxoSmithKline